Floatz logo

Elacestrant

ER Wildtype

Kristina A. FanucciSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

18 Active assets in the ER Wildtype cohort.

Asset / SponsorPhaseRating
Carboplatin
Northwestern University
Phase 3BBB
Pembrolizumab
Massachusetts General Hospital
Phase 2BB
Epirubicin
Massachusetts General Hospital
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
University of Washington
Phase 3BB
Cyclophosphamide
Massachusetts General Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

Elacestrant is also rated in:

hormone receptor-positive breast cancerDormant
BB
Indicative ·
70 / 100
View asset →
estrogen-receptor positive breast cancerDormant
BB
Indicative ·
68 / 100
View asset →
breast cancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →